GSA Capital Partners LLP Grows Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

GSA Capital Partners LLP grew its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 138.5% in the third quarter, Holdings Channel.com reports. The firm owned 608,585 shares of the company’s stock after acquiring an additional 353,384 shares during the quarter. GSA Capital Partners LLP’s holdings in Zentalis Pharmaceuticals were worth $2,240,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Anfield Capital Management LLC acquired a new position in Zentalis Pharmaceuticals during the second quarter worth $40,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $58,000. Algert Global LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $78,000. Finally, Carson Advisory Inc. increased its position in Zentalis Pharmaceuticals by 55.8% during the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after purchasing an additional 8,800 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price for the company in a research note on Monday, August 12th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.25.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $4.03 on Tuesday. The company has a market capitalization of $286.57 million, a PE ratio of -1.48 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $18.07. The firm has a 50 day moving average price of $3.38 and a 200 day moving average price of $5.59.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter last year, the business earned ($1.85) earnings per share. As a group, equities research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -3.02 earnings per share for the current year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.